Overexpressed FOXC2 in ovarian cancer enhances the epithelial-to- mesenchymal transition and invasion of ovarian cancer cells

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2545-2554

  Liu, Bo ^a   Han, Shu Mei ^a   Tang, Xiao Yong ^a   Han, L I ^a   Li, Chang Zhong ^b  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Epithelial to mesenchymal transition; Forkhead box protein C2; Invasion; Ovarian cancer

Indexed keywords

TRANSCRIPTION FACTOR FOXC2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; FORKHEAD TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL; CANCER TISSUE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84902133689     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3119     Document Type: Article

References (38)

1. Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366, 2005. (Pubitemid 40637827)
2. Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 38: 272-283, 2012.
3. Davidson B, Tropé CG and Reich R: Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2: 33, 2012.
4. Comamala M, Pinard M, Theriault C, et al: Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 104: 989-999, 2011.
5. Cheng JC, Auersperg N and Leung PC: EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One 7: e34071, 2012.
6. Cheng JC, Auersperg N and Leung PC: TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS One 7: e42436, 2012.
7. Bagnato A and Rosanò L: Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185: 85-94, 2007. (Pubitemid 46956847)
8. Ahmed N, Thompson EW and Quinn MA: Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 213: 581-588, 2007. (Pubitemid 350058249)
9. Elloul S, Vaksman O, Stavnes HT, Tropé CG, Davidson B and Reich R: Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis 27: 161-172, 2010.
10. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009.
11. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654, 2008.
12. Wang Y, Wen M, Kwon Y, et al: CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res 74: 520-532, 2013.
13. Huang RY, Chung VY and Thiery JP: Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets 13: 1649-1653, 2012.
14. Wang Y, Liu Y, Lu J, et al: Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem Biophys Res Commun 434: 352-356, 2013.
15. Lu J, Wen M, Huang Y, et al: C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics 8: 571-583, 2013.
16. Wang Y, Ma G, Wang Q, et al: Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules 19: 159-176, 2013.
17. Rosano L, Spinella F, Di Castro V, et al: Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65: 11649-11657, 2005. (Pubitemid 41821725)
18. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007. (Pubitemid 46809165)
19. Hollier BG, Tinnirello AA, Werden SJ, et al: FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 73: 1981-1992, 2013.
20. Nishida N, Mimori K, Yokobori T, et al: FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 18: 535-542, 2011.
21. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K and Mizutani S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 62: 2753-2757, 2002. (Pubitemid 34525756)
22. Mortazavi F, An J, Dubinett S and Rettig M: p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res 8: 762-774, 2010.
23. Fu J, Lv X, Lin H, et al: Ubiquitin ligase cullin 7 induces epithelial-mesenchymal transition in human choriocarcinoma cells. J Biol Chem 285: 10870-10879, 2010.
24. Yuan H, Kajiyama H, Ito S, et al: ALX1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. Cancer Res 73: 1581-1590, 2013.
25. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
26. Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166, 2009.
27. Katsuno Y, Lamouille S and Derynck R: TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84, 2013.
28. Wendt MK, Allington TM and Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5: 1145-1168, 2009.
29. Nougaret S, Addley HC, Colombo PE, et al: Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics 32: 1775-1803, 2012.
30. Tsai JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27: 2192-2206, 2013.
31. Zhu JL, Song YX, Wang ZN, et al: The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology 62: 1038-1048, 2013.
32. Watanabe T, Kobunai T, Yamamoto Y, et al: Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int Surg 96: 207-216, 2011.
33. Mani SA, Yang J, Brooks M, et al: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104: 10069-10074, 2007. (Pubitemid 47175264)
34. Seo S, Fujita H, Nakano A, Kang M, Duarte A and Kume T: The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol 294: 458-470, 2006. (Pubitemid 43884821)
35. Cederberg A, Grände M, Rhedin M, Peng XR and Enerbäck S: In vitro differentiated adipocytes from a Foxc2 reporter knock-in mouse as screening tool. Transgenic Res 18: 889-897, 2009.
36. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
37. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272, 2006.
38. Chou JL, Chen LY, Lai HC and Chan MW: TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 14: 1213-1223, 2010.